Company intelligence / Profile preview

NovelMed Therapeutics

Cleveland, Ohio, United Statesnovelmed.com ↗

Ownership: Private
Employees: ~12
Development stage: Phase 2

Overview

NovelMed’s lead candidate NM8074 has shown promising proof-of-concept data in a Phase II trial for PNH. Both NM5072 and NM8074 have completed Phase I trials with no safety concerns. The company’s approach selectively blocks the alternative complement pathway while sparing the classical pathway—potentially offering a favorable safety profile without black-box warnings. Several other antibody candidates are in preclinical development for rare diseases driven by alternative pathway dysregulation.

Therapeutic areas: RheumatologyNephrologyOphthalmologyHematologyNeurology
Modalities: Monoclonal antibodies (mAbs)Humanized antibodiesBispecific antibodies (patented)
Industry: Biotech

Drug pipeline

5 assets

ruxoprubart

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on NovelMed Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NovelMed Therapeutics.

Explore the full profile